S8 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Study populations of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Future research directions. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

PRISMA flow diagram. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S9 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S7 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Participant characteristics of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

MXene/Bi₂O₃ Nanocomposites as Supercapacitors for Portable Electronic Devices by Nanasaheb M. Shinde (8560572)

“…2D MXene nanosheets often encounter challenges such as aggregation and restacking, which can significantly decrease their performance in supercapacitor applications. …”

Image 3_Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition.jpeg by Bruno K. Rodiño-Janeiro (20565584)

“…However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction.…”

Image 1_Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition.jpeg by Bruno K. Rodiño-Janeiro (20565584)

“…However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction.…”

Image 2_Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition.jpeg by Bruno K. Rodiño-Janeiro (20565584)

“…However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction.…”

Image 4_Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition.jpeg by Bruno K. Rodiño-Janeiro (20565584)

“…However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction.…”

DataSheet1_Pharmacological inhibition of receptor protein tyrosine phosphatase β/ζ decreases Aβ plaques and neuroinflammation in the hippocampus of APP/PS1 mice.docx by Teresa Fontán-Baselga (20392470)

“…In addition, we observed a significant decrease in the number and size of astrocytes in both sexes and in the number of microglial cells in a sex-dependent manner. …”

Data Sheet 1_Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects.docx by Yajie He (20323682)

“…<p>Y-shape branched PEGylated recombinant human growth hormone (YPEG-rhGH) is a suitable drug for the treatment of growth hormone deficiency. …”

Seven forecast scenarios. by Ryan P. Thombs (9138968)

“…We find that a decrease in expenditures has a larger effect on decreasing energy consumption than an increase in expenditures does on increasing consumption. …”

Forecast for each scenario, 2023-2032. by Ryan P. Thombs (9138968)

“…We find that a decrease in expenditures has a larger effect on decreasing energy consumption than an increase in expenditures does on increasing consumption. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”